Latest news with #neurodegenerativeDiseases
Washington Post
28-05-2025
- Health
- Washington Post
Scientists develop gene delivery ‘trucks' that could treat brain diseases
Scores of researchers have produced new tools that can deliver genes and selectively activate them in hundreds of different cell types in the brain and spinal cord, a breakthrough that scientists hope advances them toward developing targeted therapies to treat neurodegenerative diseases such as ALS, Parkinson's disease and Alzheimer's. The discoveries, made through the National Institutes of Health's BRAIN initiative, show with unprecedented clarity and precision how neural cells work together, but also how diseases disrupt their tight choreography. The insight offers the promise that doctors may one day treat diseases by manipulating dysfunctional cells.
Associated Press
27-05-2025
- Business
- Associated Press
VectorY Therapeutics Appoints Jessica Atkinson as Chief Business Officer
AMSTERDAM & BOSTON--(BUSINESS WIRE)--May 27, 2025-- VectorY Therapeutics, a biotechnology company developing innovative vectorized antibody therapies for the treatment of neurodegenerative diseases, today announced the appointment of Jessica Atkinson as Chief Business Officer (CBO). In this newly created role, Atkinson will partner with the Chief Executive Officer and management team to develop long-term business and commercial strategies that support company growth, and will also drive strategic partnerships. This press release features multimedia. View the full release here: Jessica Atkinson, New CBO at VectorY Therapeutics Atkinson brings over two decades of business development and commercialization experience across biopharmaceutical companies and innovative startups. She has held leadership roles at ImmuneID, Glympse Bio, and Foundation Medicine, where she spearheaded strategic partnerships and corporate strategy initiatives. She also held roles of increasing responsibility over seven years in the U.S. commercial organization of Merck & Co. Most recently, Atkinson served as a fractional CBO or strategic advisor to multiple early-stage biotech companies through her consulting firm, TwoStep Advisors. 'I'm delighted to welcome Jessica to VectorY,' said Jim Scibetta, chief executive officer of VectorY Therapeutics. 'Her proven expertise in shaping strategy and driving successful transactions across all stages of drug development will be invaluable as we advance our pipeline and pursue new opportunities. Jessica's collaborative approach and strategic vision make her an ideal addition to our leadership team.' 'VectorY's pioneering approach to developing vectorized antibody therapeutics holds immense promise for patients with neurodegenerative diseases,' said Atkinson. 'I look forward to working closely with the management and research teams to further develop our corporate strategy and to create transformative alliances and business collaborations that support the company's mission and long-term success.' Atkinson holds a Bachelor of Science degree in Molecular Biology from the University of Texas, Austin. She has been an advocate for encouraging women to pursue careers in science and volunteers with Mass General Cancer Center's Peer Mentoring program that offers patients and family members the opportunity to speak by telephone one-to-one with an experienced patient. About VectorY VectorY is on a mission to provide people with neurodegenerative diseases a longer, better life by creating transformative vectorized antibody treatments. Our platform combines the promise of precise therapeutic antibodies with one-time AAV-based delivery to the CNS. Unique in-house expertise in antibodies, AAV vectors, protein degradation, manufacturing and neuroscience drives the rapid development of much needed disease-modifying therapies for neurodegenerative diseases such as ALS and Huntington's disease. For more information, see View source version on CONTACT: VectorY Therapeutics B.V. E-mail:[email protected] Tel: +31 20 226 8020 Vigo Consulting (Media) Melanie Toyne-Sewell / Rozi Morris E-mail:[email protected] Tel: +44 207 390 0237 / +44 20 7390 0231 KEYWORD: MASSACHUSETTS EUROPE UNITED STATES NETHERLANDS NORTH AMERICA INDUSTRY KEYWORD: SCIENCE NEUROLOGY OTHER SCIENCE BIOTECHNOLOGY RESEARCH PHARMACEUTICAL HEALTH CLINICAL TRIALS SOURCE: VectorY Therapeutics Copyright Business Wire 2025. PUB: 05/27/2025 07:05 AM/DISC: 05/27/2025 07:05 AM
Globe and Mail
07-05-2025
- Business
- Globe and Mail
This Biotech Found Mid-Week Success Following Analyst Upgrade
A biotech company based out of Massachusetts found a tremendous amount of success on Wednesday after Leerink Partners upgraded the stock from market perform to outperform, raising their price target for the stock from $4 to $10. Traders wasted no time buying up shares of Amylyx Pharmaceuticals Inc. (Nasdaq:AMLX), pushing the small cap to close up at $4.87/share (+4.73%) on the day. This doesn't come at too much of a surprise given the bullish price target versus yesterday's close at just $4.65. This move was a strong continuation of the success this stock has had over the last month. Amylyx Pharmaceuticals Inc is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis and other neurodegenerative diseases. Copyright © 2025 All rights reserved. Republication or redistribution of content is expressly prohibited without the prior written consent of shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. View more of this article on About Media, Inc.: Founded in 1999, is one of North America's leading platforms for micro-cap insights. Catering to both Canadian and U.S. markets, we provide a wealth of resources and expert content designed for everyone—from beginner investors to seasoned traders. is rapidly gaining recognition as a leading authority in the micro-cap space, with our insightful content prominently featured across numerous top-tier financial platforms, reaching a broad audience of investors and industry professionals. Want to showcase your company's story to a powerful network of investors? We can help you elevate your message and make a lasting impact. Contact us today. Contact: Media, Inc.
